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ABSTRACT
Objectives: This cross-sectional study was conducted during the year 2014–15 to determine the prevalence, pattern, and factors associated with left 
ventricular hypertrophy (LVH) among hypertensive patients attending a tertiary care hospital.
Methods: A total of 400 eligible adult patients having essential hypertension were included in this study. After obtaining informed consent, all 
participants were examined with echocardiography and relevant information was collected using a well-structured questionnaire.
Results: The mean age of study population was 52.3 ± 12.8 in years. Mean systolic (SBP) and diastolic blood pressure (DBP) was 149.8 ± 11.2 and 
94.7 ± 4.9 mmHg, respectively. Among the study participants, 266 (66.5%) had LVH and concentric hypertrophy was the predominant (64.3%) LV 
geometric pattern. Multivariate logistic regression revealed that obesity, SBP, and DBP had significant positive association with LVH (p<0.05).
Conclusion: Liberal use of echocardiography in hypertensive patients could be useful in early diagnosis of LVH and guiding treatment decision. 
There should be emphasis on controlling SBP, DBP, and body mass index of hypertensive patients so that further cardiovascular complications can be 
prevented.
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INTRODUCTION
Cardiovascular diseases (CVDs) constitute one of the major causes of 
death and disabilities in the world. An estimated 17.7 million people 
died from CVD in 2015, representing 31% of all global deaths. Of 
the 17 million premature deaths (under the age of 70) due to non-
communicable diseases in 2015, 82% are in low- and middle-income 
countries, and 37% are caused by CVD [1]. It is predicted that there 
will be a 60% rise in hypertensive adult patients from 972 million in 
2000 to 1.56 billion in 2025 worldwide [2]. Hypertension is a powerful 
predictor of cardiovascular morbidity and mortality with significant 
disability [3-5] and directly responsible for 57% of all stroke deaths; 
24% of all coronary heart disease deaths in India [6]. Blood pressure 
reduction is highly efficacious in protecting patients against stroke and 
stroke recurrence, especially on long-term basis [7].
Left ventricular hypertrophy (LVH) is one of the earliest 
manifestations of organ damage among hypertensive patients and 
is a strong independent predictor of cardiovascular mortality and 
morbidity [8-11]. It has been shown in various studies that the 
incidence of LVH increases with age, obesity, gender, and blood 
pressure [12-16]. The relationship between LV mass and the degree 
of obesity has also been demonstrated by the Framingham study. 
Early diagnosis of LVH, risk stratification, and aggressive treatment 
is essential to prevent cardiovascular morbidity and mortality [17]. 
It has been reported that assessment of cardiovascular risks among 
hypertensive patients are inadequate [18] and information regarding 
LVH in hypertensive patients is scarce, especially in this region. In this 
context, the present study was conducted with the aim to assess the 
prevalence and pattern of LVH and determine its associated factors 
among hypertensive patients.
METHODS
This is a cross-sectional descriptive study conducted at IMS and SUM 
Hospital, Bhubaneswar, in the Department of Cardiology/Physiology 
including 400 hypertensive patients who attended cardiology OPD 
from May 2014 to April 2015. All the study participants were explained 
about the nature and purpose of the study; informed consent was 
obtained before their participation in the study. All eligible study 
individuals were examined with echocardiography and relevant 
information was obtained using a well-structured questionnaire. 
Assuming the prevalence of echocardiographic LVH as 45% [19] with 
absolute precision 5% and 95% confidence interval, the sample size 
was calculated as 380. However, we included 400 patients in our study. 
The study was approved by the Institutional Ethics Committee of the 
authors’ institution and all procedures followed were in accordance 
with appropriate ethical guidelines.
Inclusion criteria
Adults’ ≥18 years of age diagnosed to have essential hypertension with 
or without medication and willing to participate in the study.
Exclusion criteria
The presence of known cardiac diseases including valvular heart 
disease, coronary artery disease, conduction abnormalities; systemic 
diseases such as diabetes mellitus, chronic kidney disease, chronic 
obstructive pulmonary disease, tuberculosis, hepatic disease, and 
cancer.
Height of the study subjects was measured using stadiometer and the 
reading was taken to the nearest 0.5 cm. Weight was measured using a 
weighing machine with the subjects wearing only light clothing. Body mass 
index (BMI) was calculated as weight in kilogram divided by the square of 
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the height in meters (kg/m2). BMI cutoff values for Asians as per the NICE 
guideline were followed to define obesity as having BMI ≥27.5, overweight 
with BMI 23–27.5 kg/m2, normal 18.5–23 kg/m2, and underweight 
<18·5 kg/m2 [20]. The body surface area (BSA) was determined by Dubois 
formula (BSA =0.007184 × Height0.725 × Weight0.425) [21]. Blood pressure 
was measured using standardized mercury sphygmomanometer to 
determine brachial artery systolic (SBP) and diastolic blood pressure 
(DBP). The blood pressure was measured by a cardiologist after 5 min 
rest in erect sitting posture over the left upper arm of the study subjects. 
The first and fifth Korotkoff sounds were taken as SBP and DBP. The 
blood pressure ≥140/90 mmHg was considered to be hypertensive 
according to JNC7 criteria. The blood pressure was taken as mean of 
two readings measured under standardized conditions. 2D and M-mode 
echocardiography was performed in all the study participants using a 
commercially available GE Vivid E9 with XD clear (echocardiography 
machine equipped with a broadband transducer) in supine left lateral 
decubitus position. All echocardiographic measurements were performed 
by a cardiologist. Readings were taken as per the American Society 
of Echocardiography (ASE) recommendation. The M-mode derived 
parasternal view was used to assess the chamber and wall dimensions of 
the left ventricle and left atrium (LA). The ASE recommended Devereux 
formula was used for the estimation of the LV mass (LVM) from LV linear 
dimensions [LVM (g) = 1.04 ((LVIDd + IVSd + LVPWd)3 – LVIDd3) – 13.6, 
where, LVID = LV internal diameter at end diastole, IVSD = interventricular 
septal wall thickness at end diastole, LVPWD = LV posterior wall thickness 
at end diastole].
LVM index (LVMI) was obtained as a ratio of LVM and BSA (LVM/
BSA). Gender-specific and indexation of LVM was used to diagnose 
LVH using the defining criteria for men and women, respectively [22]. 
LVH was defined by LVMI thresholds of 125 g/m2 for men and 110 g/
m2 for women. The relative wall thickness (RWT) was calculated using 
the formula ×2 LVPWD/LVID and considered as increased when it is 
>0.42 [23]. RWT and LVMI were used to define LV geometric patterns. 
LV geometry was divided into four patterns based on LVMI and RWT 
values; normal geometry: Normal LVMI and RWT ≤0.42, concentric 
remodeling: Normal LVMI and RWT >0.42, eccentric hypertrophy: 
Increased LVMI and RWT ≤0.42, and concentric hypertrophy: Increased 
LVMI and RWT >0.42. LA size was determined with parasternal long 
axis view at end systole along its greatest dimension.
Statistical analysis
All the data were compiled and analyzed using SPSS version 21.0 
software and values were expressed as mean, standard deviation, 
proportion, odds ratio, and 95% confidence interval. Univariate and 
multivariate logistic regression analyses were used to explore the 
associations between LVH as dependent variable and sociodemographic 
and individual characteristics as independent variables. The variables 
found to have p<0.2 in univariate analyses were entered into 
multivariate model. p<0.05 was considered as statistically significant.
RESULTS
Of 400 study respondents, 247 (61.7%) were male and rest were 
female. The mean age of study population was 52.3 ± 12.8 years. The 
mean BMI was 26.7 ± 4.6 and the mean BSA was 1.6 ± 0.2. The mean 
SBP and DBP was 149.8 ± 11.2 and 94.7 ± 4.9 mmHg, respectively.
The sociodemographic characteristics of study population were shown 
in Table 1. Majority (50.7%) of respondents belongs to age range 
of 41–60 years and 30.2% were >60 years old. About 331 (82.7%) 
respondents were overweight or obese. It was observed that almost 
two-third of hypertensive patients had LVH. Variables such as BMI, SBP, 
DBP, and left atrial diameter were found significantly associated with 
LVH in hypertensive patients.
Table 2 summarizes the LV geometric pattern among the hypertensive study 
population. Abnormal LV geometry was seen in almost all study subjects 
(98.7%). Concentric hypertrophy was the predominant (64.3%) pattern 
followed by concentric remodeling (32.3%) among the hypertensives.
Multivariate analysis showing associations of variables with LVH is 
given in Table 3. Left atrial diameter lost its significance, whereas BMI, 
SBP, and DBP retained their significance in predicting LVH among the 
hypertensive patients.
DISCUSSION
Our study revealed that 66.5% of hypertensive patients had developed 
LVH. This figure was comparable to the prevalence of 58.3–75.3% 
[24-26] in various studies which used the same LVH criteria as in our 
study. It was higher compared to many other studies, which reported 
prevalence of LVH between 26.8% and 46.0% [27-30]. As for LV 
geometric patterns, we observed that the concentric pattern was 
more prevalent among hypertensive patients. Different studies have 
shown the association of incremental risk of abnormal geometric 
patterns, with highest in concentric hypertrophy, followed by 
eccentric hypertrophy and concentric remodeling [31-34]. The study 
by Patel et al. and Potu et al. revealed that concentric remodeling 
(38.5–52.1% and 30%) was the most common abnormal geometry 
in the hypertensive population followed by concentric hypertrophy 
(15.3–28.9% and 14%) and eccentric hypertrophy (3.99–10.3% 
and 11%) which was the least common type of abnormal geometry 
[35,36]. Studies showed that eccentric hypertrophy was the most 
common abnormal geometry found in hypertensive population by 
Adebiyi et al., Cuspidi et al., and Wachtell et al. [19,37,38] whereas 
Akintunde et al. found that majority of hypertensive subjects had 
concentric remodeling [39]. There is global and cellular change in the 
ventricular shape and function in cardiac remodeling. This follows 
chamber dilation, interstitial and perivascular fibrosis which lead to 
chronic heart failure [40]. There is an increasing body of evidence 
and controversies about the role of gender in developing LVH 
[12,13,15,19]. Our study did not show significant difference between 
gender and LVH.
Previous studies reported that patients with obesity had a higher risk of 
developing LVH [40-45]. In this study, obesity was found to be one of the 
predictors for developing LVH among hypertensive patients. The odds 
of developing LVH were twice in an obese patient compared to a patient 
who had normal weight. Further, the odds of developing LVH were 1.4 
times higher for an obese patient compared to an overweight patient, 
but this is statistically insignificant. Kathrotia et al. also showed similar 
trend in association of obesity with LVH [46]. This might be related 
to obesity cardiomyopathy which is characterized by the presence of 
LVH [47]. We also observed that SBP and DBP were two independent 
determinants for LVH which indicates that reduction of SBP or DBP 
would significantly regress LVH. This finding is supported by various 
literature [48-50]. Thus, blood pressure management targeting both 
SBP and DBP would be useful in preventing the development of LVH. 
The left atrial enlargement is a predictor for overall cardiovascular risk 
and frequently found in hypertensive patients as reported by Cuspidi 
et al. [19]. This abnormality was strongly related to LVH [51-53]. This 
study showed that LVH was 1.4 times more likely among hypertensives 
with one unit increase in left atrial diameter (p=0.088). For this reason, 
European Society of Cardiology strongly recommends the measurement 
of left atrial size in echocardiography.
Our study few limitations. First, the result of the study may not be 
generalized to other settings since it was limited to one tertiary care 
hospital in Bhubaneswar. Second, causal association of the factors with 
the development of LVH cannot be established due to cross-sectional 
nature of the study. However, in spite of these limitations, the findings 
of our study might be useful in developing strategies to identify LVH 
among hypertensive patients.
CONCLUSION
LVH is the alarming and significant rising condition in hypertension. 
The prevalence of LVH was high in hypertensive patients as found in 
our study. Efforts should be made for early detection of LVH with liberal 
use of echocardiography in these patients which will guide appropriate 
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treatment decision, and thus further cardiovascular complications can 
be prevented.
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